Clinical trials
NETs clinical trials
Below are recruiting nets clinical trials, each written for real people, not researchers. We’re tracking 72 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07716280Recruiting
Text message help for lung cancer screening in safety-net clinics
This study tests if text messages can help people who are at risk for lung cancer get screened. If you are a current or former smoker between 50 and 80 years old, and speak English or Spanish, this may help remind you or guide you to get a lung cancer check.
Salt Lake City, UtahAges 50–80 - NCT07299981Recruiting
Brain water changes after clot-busting drug for stroke
This study looks at how much water builds up in brain tissue after a stroke is treated with a clot-busting drug. It may help doctors understand who will recover better.
ViennaAges 18 years+ - NCT04086485RecruitingPhase 1/Phase 2
Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Bethesda, MarylandAges 18–100 - NCT04324502Recruiting
Phone app study to collect symptom reports in NET
This study tests a mobile phone app that helps people with neuroendocrine tumors (NETs) report symptoms and quality of life. It may help by making it easier to track how you’re doing during treatment using questionnaires.
LondonAges 18 years+ - NCT04339036RecruitingPhase 2
CapTem plus Y-90 for liver-spread neuroendocrine tumors
This Phase 2 study tests whether combining capecitabine/temozolomide (“CapTem”) with Y-90 treatment can shrink neuroendocrine tumor (NET) spread in the liver. It may help people whose tumor is mostly in the liver and cannot be fully removed with surgery.
La Jolla, CaliforniaAges 18 years+ - NCT04735198Recruiting
Preventive gallbladder removal for midgut neuroendocrine tumors
This trial looks at whether removing the gallbladder before it causes problems can be helpful for people with midgut neuroendocrine tumors who are already planning primary tumor surgery. It may reduce future gallbladder-related complications around the time of cancer treatment.
Badalona, BarcelonaAges 18 years+ - NCT04837885RecruitingPhase 2
Liver-targeted radioactive drug for GI or pancreas NET liver spread
This study tests a way to deliver a radioactive “somatostatin-type” medicine directly into the liver artery to treat liver-dominant spread of neuroendocrine tumors (NETs). It may help shrink or control liver metastases after standard treatment has not worked enough.
BordeauxAges 18 years+ - NCT04847505RecruitingPhase 3
Testing 68Ga-DOTA-TATE PET/CT scans for neuroendocrine tumors
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
Montreal, QuebecAges Any age - NCT04954820RecruitingPhase 2
Second round Lutathera for intestinal NET after regrowth
This Phase 2 study looks at whether giving Lutathera again (a second round) can control an intestinal neuroendocrine tumor (NET) that came back or progressed after the first treatment. It mainly targets adults whose scan shows tumors still take up the right “target” signal and who previously benefited for at least 12 months.
AngersAges 18 years+ - NCT05165407RecruitingPhase 2
Study drugs for advanced high-grade neuroendocrine tumors
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT05572632Recruiting
COPD wellness rehab program for safety-net patients
This trial studies a COPD (chronic lung disease) wellness and rehabilitation program for people who get care through the safety-net health system. It may help improve day-to-day outcomes by supporting safer exercise and better COPD management.
San Francisco, CaliforniaAges 40–90 - NCT05673031Recruiting
PET/CT scan test for neuroendocrine tumors with a special tracer
This study uses a PET/CT scan with a small amount of radioactive tracer to see how neuroendocrine tumors are behaving in adults. It may help doctors better detect and evaluate these tumors, especially when symptoms suggest a carcinoid-type hormone problem.
Calgary, AlbertaAges 18–100 - NCT05711173Recruiting
Study blood clot triggers and immune cell changes in clot patients
This study looks at how certain blood cell changes and immune system activity may relate to blood clots in specific veins or lungs. It may help researchers understand why clots happen “without a clear cause” and how to better predict risk.
BordeauxAges 6–50 - NCT05734430Recruiting
Study of genetics in appendix cancer families
This study looks at genetic (inherited) and other biological factors in people with appendix cancer and, in some cases, their biological parents. The goal is to learn what may contribute to appendix cancer and help researchers better understand risk.
Nashville, TennesseeAges 18 years+ - NCT05971225Recruiting
Testing remote heart monitoring to improve heart outcomes
This study checks whether starting remote wireless heart monitoring for people with heart failure helps improve important heart outcomes. It may help your care team catch warning signs earlier by receiving your heart data from home.
Suwon, Kyonggi DoAges 20 years+ - NCT06043193Recruiting
Quality of life study for patients with neuroendocrine tumors getting internal radiation therapy
This study looks at how internal radiation therapy (RIV) affects quality of life in people with neuroendocrine tumors. It aims to understand how well patients tolerate this treatment and how it impacts daily life.
Saint-Priest-en-Jarez, Saint-EtienneAges 18 years+ - NCT06170268Recruiting
Alzheimer's registry for treatment and diagnosis
This registry collects information from people with mild cognitive impairment or dementia due to Alzheimer's disease who are being treated with new FDA-approved therapies. The goal is to track how these treatments work in everyday medical practice.
Chicago, IllinoisAges 18 years+ - NCT05999084Enrolling by invitation
Georgia Memory Net Anti-Amyloid Antibody Study
This study tests antibody treatments that target amyloid plaques in the brain for people with mild memory or thinking problems. It may help determine if you are a candidate for these new drugs and monitors your safety through regular scans and checkups.
Albany, GeorgiaAges 50–90 - NCT05785780Enrolling by invitation
Help improve colon cancer screening for people with diabetes
This study looks for better ways to make sure people with diabetes get up-to-date colon cancer screening. If you haven’t had the recommended test on time, it may help identify barriers in primary care and improve screening follow-through.
New Brunswick, New JerseyAges 50–74 - NCT06327542Recruiting
Group pain management in primary care clinics
This trial tests a group-based program to help people with chronic pain manage their symptoms. It is offered in primary care clinics that serve underinsured communities, and sessions are available in English or Spanish.
San Francisco, CaliforniaAges 18 years+ - NCT06343428Recruiting
New classification system for NET G3 patients
This trial studies a new way to classify and predict outcomes for people with a specific type of neuroendocrine tumor (NET G3). It uses tumor tissue and past scans to better understand your cancer and guide treatment.
MilanAges 18 years+ - NCT06356467Recruiting
How tumor and patient factors affect GEP-NEN treatment response
This study looks at how tumor and patient factors affect treatment response in well-differentiated GEP-NENs (neuroendocrine tumors of the digestive system). It may help doctors understand which treatments work best for people like you.
MilanAges 18 years+ - NCT06451718Recruiting
A new implant for keratoconus to avoid corneal transplant
This trial tests a small metal implant placed in the cornea to treat keratoconus, a condition where the cornea thins and bulges. The goal is to see if the implant can safely improve vision and prevent the need for a corneal transplant.
Roma, RomaAges 18 years+ - NCT06455358RecruitingPhase 1/Phase 2
A new PET scan to find neuroendocrine tumors
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
Basel, Canton of Basel-CityAges 18 years+
Hear when a new NETs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nets?
- Yes. Clin2 currently lists 72 recruiting nets studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nets trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nets trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.